Table 2.
Outcome characteristics stratified by definite antimicrobial therapy
| Definite carbapenem treatment (n = 162) | Definite cefepime treatment (n = 77) | p-value | |||
|---|---|---|---|---|---|
| n/ median | %/ IQR | n/ median | %/IQR | ||
| Primary outcomes | |||||
| In-hospital death | 25 | 15.4 | 6 | 7.8 | 0.148 |
| New renal impairment | 22 | 13.6 | 6 | 7.8 | 0.281 |
| Neurological adverse events | 34 | 21.0 | 4 | 5.2 | 0.001 |
| Secondary outcomes | |||||
| Length of stay (survivors) | 23.0 | 12.0–37.0 | 17.0 | 9.0–30.0 | 0.031 |
| First recurrent infection with AmpC-PE a | 19 | 11.7 | 5 | 6.5 | 0.255 |
| Second recurrent infection with AmpC-PE a | 3 | 15.8b | 2 | 40.0b | 0.270 |
Abbreviations: AmpC-PE AmpC-producing Enterobacterales, IQR interquartile range, n number
ain the following 6 months, bout of total first recurrent infection with AmpC-PE